Biocon has received 6 observations from the US health regulator, after it had inspected its Malaysia manufacturing facility. The company in a regulatory filing stated,...
Biocon has entered into a global partnership with Sandoz, a division of Swiss pharmaceutical Novartis. As per the terms of agreement, both companies will develop,...
USFDA has given approval to Mylan’s Ogivri, which is a biosimilar of cancer drug Herceptin, co-developed with Biocon. Trastuzumab is the generic name of Herceptin. Ogivri has received...
Biocon has launched KRABEVA, a biosimilar Bevacizumab, in India. It is used for treating patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian...
Biocon has received the Establishment Inspection Report, from the USFDA with voluntary action indicated status, on closure of inspection of its aseptic drug product facility....
As per Biocon, the US health regulator has issued complete response letter (CRL) for proposed biosimilar Pegfilgrastim, which is to be used in treatment for...
Biocon, the bio pharmaceutical firm and its partner Quark Pharmaceuticals has received the Drug Controller General of India (DCGI)’s approval to proceed with clinical trials...
On Tuesday, the Biotechnology major Biocon has posted an increases in its consolidated net profit at Rs 306 crore for the second quarter ended September...
The company has filed prospectus with the capital market regulator SEBI for the initial public offer of its research arm Syngene on Wednesday. The company...